BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 46 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q4 2022. The put-call ratio across all filers is 0.16 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $22,631 | -84.4% | 144,356 | +24.9% | 0.01% | -84.4% |
| Q2 2023 | $145,002 | -42.8% | 115,613 | +23.5% | 0.06% | -44.8% |
| Q1 2023 | $253,379 | +114.4% | 93,613 | -21.6% | 0.12% | +93.3% |
| Q4 2022 | $118,200 | -72.8% | 119,447 | -27.2% | 0.06% | -75.9% |
| Q3 2022 | $435,000 | +50.5% | 163,972 | +56.7% | 0.25% | +53.7% |
| Q2 2022 | $289,000 | -33.9% | 104,653 | -19.5% | 0.16% | -23.6% |
| Q1 2022 | $437,000 | -29.7% | 130,000 | -16.4% | 0.21% | -29.1% |
| Q4 2021 | $622,000 | +265.9% | 155,500 | +201.9% | 0.30% | +225.0% |
| Q3 2021 | $170,000 | -8.6% | 51,500 | +5.4% | 0.09% | -12.4% |
| Q2 2021 | $186,000 | -3.1% | 48,881 | -2.2% | 0.10% | -11.0% |
| Q1 2021 | $192,000 | – | 50,000 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | 242,850 | $923,000 | 0.13% |
| ABNER HERRMAN & BROCK LLC | 241,500 | $918,000 | 0.13% |
| Weaver Consulting Group | 48,881 | $186,000 | 0.10% |
| Tibra Equities Europe Ltd | 87,000 | $331,000 | 0.10% |
| Ikarian Capital, LLC | 293,200 | $1,115,000 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 60,238 | $229,000 | 0.03% |
| Ergoteles LLC | 124,329 | $472,000 | 0.01% |
| CFO4Life Group, LLC | 12,003 | $46,000 | 0.01% |
| HighPoint Advisor Group LLC | 17,033 | $65,000 | 0.01% |
| BOOTHBAY FUND MANAGEMENT, LLC | 32,836 | $125,000 | 0.00% |